KR102240323B1 - 유방암 전이의 진단, 예후 및 치료 방법 - Google Patents

유방암 전이의 진단, 예후 및 치료 방법 Download PDF

Info

Publication number
KR102240323B1
KR102240323B1 KR1020197001458A KR20197001458A KR102240323B1 KR 102240323 B1 KR102240323 B1 KR 102240323B1 KR 1020197001458 A KR1020197001458 A KR 1020197001458A KR 20197001458 A KR20197001458 A KR 20197001458A KR 102240323 B1 KR102240323 B1 KR 102240323B1
Authority
KR
South Korea
Prior art keywords
maf
gene
breast cancer
metastasis
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197001458A
Other languages
English (en)
Korean (ko)
Other versions
KR20190009835A (ko
Inventor
카브레 로저 고미스
서니어 마리아 타라고나
에스타페 안나 아르날
밀리카 파블로빅
Original Assignee
펀다시오 인스티튜트 드 르세르카 바이오메디카(아이알비 바르셀로나)
인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES201031478A external-priority patent/ES2379918B1/es
Application filed by 펀다시오 인스티튜트 드 르세르카 바이오메디카(아이알비 바르셀로나), 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠 filed Critical 펀다시오 인스티튜트 드 르세르카 바이오메디카(아이알비 바르셀로나)
Publication of KR20190009835A publication Critical patent/KR20190009835A/ko
Application granted granted Critical
Publication of KR102240323B1 publication Critical patent/KR102240323B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
KR1020197001458A 2010-10-06 2011-10-05 유방암 전이의 진단, 예후 및 치료 방법 Active KR102240323B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ESP201031478 2010-10-06
ES201031478A ES2379918B1 (es) 2010-10-06 2010-10-06 Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama.
ESP201131073 2011-06-27
ES201131073 2011-06-27
PCT/ES2011/070693 WO2012045905A2 (es) 2010-10-06 2011-10-05 Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137011176A Division KR101944555B1 (ko) 2010-10-06 2011-10-05 유방암 전이의 진단, 예후 및 치료 방법

Publications (2)

Publication Number Publication Date
KR20190009835A KR20190009835A (ko) 2019-01-29
KR102240323B1 true KR102240323B1 (ko) 2021-04-14

Family

ID=45099129

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137011176A Active KR101944555B1 (ko) 2010-10-06 2011-10-05 유방암 전이의 진단, 예후 및 치료 방법
KR1020197001458A Active KR102240323B1 (ko) 2010-10-06 2011-10-05 유방암 전이의 진단, 예후 및 치료 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020137011176A Active KR101944555B1 (ko) 2010-10-06 2011-10-05 유방암 전이의 진단, 예후 및 치료 방법

Country Status (13)

Country Link
US (3) US10047398B2 (enExample)
EP (3) EP3091085B1 (enExample)
JP (5) JP6159254B2 (enExample)
KR (2) KR101944555B1 (enExample)
CN (2) CN103339265B (enExample)
AR (1) AR083357A1 (enExample)
AU (4) AU2011311452B2 (enExample)
BR (1) BR112013008505B1 (enExample)
CA (1) CA2813674C (enExample)
DK (2) DK2626431T3 (enExample)
ES (3) ES2721639T3 (enExample)
MX (2) MX344315B (enExample)
WO (1) WO2012045905A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3091085B1 (en) * 2010-10-06 2019-02-27 Institució Catalana de Recerca I Estudis Avançats Method of designing a therapy for breast cancer metastasis
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20140105918A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160032399A1 (en) * 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
WO2014140896A2 (es) * 2013-03-15 2014-09-18 Fundacio Privada Institut De Recerca Biomedica Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer
CA2906394A1 (en) * 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
MX362041B (es) * 2013-10-09 2019-01-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
EP2933639A1 (en) * 2014-04-16 2015-10-21 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts S100p and Hyaluronic acid as biomarkers for metastatic breast cancer
CN104398506A (zh) * 2014-12-09 2015-03-11 厦门大学 雷奈酸锶在制备预防和治疗腺癌药物中的新用途
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
DK3458610T3 (da) * 2016-05-25 2021-06-07 Inbiomotion Sl Terapeutisk behandling af brystcancer baseret på c-MAF-status
KR101896558B1 (ko) 2016-11-21 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
CN107699619B (zh) * 2017-11-17 2019-02-22 柳超 lncRNA组合物及制备诊断预示Luminal B型乳腺癌骨转移基因诊断试剂盒的用途
AU2018372762B2 (en) 2017-11-22 2025-08-21 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
JP2023079997A (ja) 2021-11-29 2023-06-08 東洋インキＳｃホールディングス株式会社 活性エネルギー線硬化型インクジェットインキ及び印刷物
CN114574577A (zh) * 2022-01-04 2022-06-03 中山大学孙逸仙纪念医院 Mettl16基因及其用途
CN119614707A (zh) * 2025-01-13 2025-03-14 中山大学 ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
DE4013632A1 (de) 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
EP0910652B1 (en) 1996-04-05 2014-10-08 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
DE951551T1 (de) 1996-12-23 2000-09-14 Immunex Corp., Seattle Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
HK1039108A1 (zh) 1999-03-15 2002-04-12 Axys Pharmaceuticals, Inc. 以n-氰甲基酰胺作为蛋白酶抑制剂
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
JP2003525874A (ja) 2000-01-06 2003-09-02 メルク フロスト カナダ アンド カンパニー プロテアーゼ阻害剤としての新規化合物および組成物
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
JP2005509961A (ja) 2001-11-13 2005-04-14 コーニンクレッカ　フィリップス　エレクトロニクス　エヌ　ヴィ 較正を導き出す方法および画像処理の方法
KR100485271B1 (ko) 2002-01-16 2005-04-27 메타볼랩(주) 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DE10235624A1 (de) 2002-08-02 2004-02-19 Aventis Pharma Deutschland Gmbh Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
WO2005029067A2 (en) 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing breast cancer
WO2005046731A1 (en) 2003-10-17 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
WO2005060722A2 (en) 2003-12-18 2005-07-07 President And Fellows Of Hardvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
EP1730308A4 (en) 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS
WO2006012221A2 (en) 2004-06-25 2006-02-02 The Regents Of The University Of California Target cell-specific short interfering rna and methods of use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
EP1941050B1 (en) 2005-09-20 2017-04-26 Janssen Diagnostics, LLC Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes
EP1931994A2 (en) 2005-09-26 2008-06-18 Novartis AG Molecular markers associated with bone metastasis
CA2632451C (en) 2005-12-06 2015-11-03 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
MX2009012650A (es) 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
WO2008145125A1 (en) 2007-05-31 2008-12-04 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
CA2702805A1 (en) 2007-10-18 2009-04-23 University Health Network Clioquinol for the treatment of hematological malignancies
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
CN102123708A (zh) 2008-06-06 2011-07-13 大学健康网络 用于治疗恶性血液疾病的8-羟基喹啉衍生物
EP2297360A1 (en) 2008-07-02 2011-03-23 Assistance Publique - Hôpitaux de Paris A method for predicting clinical outcome of patients with non-small cell lung carcinoma
ES2338843B1 (es) 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
WO2011017687A1 (en) 2009-08-06 2011-02-10 Ray Partha S Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
EP3091085B1 (en) 2010-10-06 2019-02-27 Institució Catalana de Recerca I Estudis Avançats Method of designing a therapy for breast cancer metastasis
US20140162887A1 (en) 2011-02-04 2014-06-12 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
US9066963B2 (en) 2011-03-15 2015-06-30 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with anthracycline therapy
WO2013075059A1 (en) 2011-11-18 2013-05-23 Vanderbilt University Markers of triple-negative breast cancer and uses thereof
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
US20140105918A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
WO2014140896A2 (es) 2013-03-15 2014-09-18 Fundacio Privada Institut De Recerca Biomedica Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
CA2906394A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
MX362041B (es) 2013-10-09 2019-01-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
DK3458610T3 (da) 2016-05-25 2021-06-07 Inbiomotion Sl Terapeutisk behandling af brystcancer baseret på c-MAF-status
AU2018372762B2 (en) 2017-11-22 2025-08-21 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eur J Cancer, 46(7): 1211-1222 (2010.03.27.)*

Also Published As

Publication number Publication date
KR20190009835A (ko) 2019-01-29
JP6159254B2 (ja) 2017-07-12
EP3517630A1 (en) 2019-07-31
AU2016266009A1 (en) 2016-12-15
KR101944555B1 (ko) 2019-02-01
MX344315B (es) 2016-12-13
HK1187377A1 (en) 2014-04-04
EP2626431B1 (en) 2015-09-16
KR20140071946A (ko) 2014-06-12
US20190169693A1 (en) 2019-06-06
JP2013541339A (ja) 2013-11-14
BR112013008505B1 (pt) 2023-01-24
US20140057796A1 (en) 2014-02-27
CN103339265A (zh) 2013-10-02
WO2012045905A2 (es) 2012-04-12
ES2911505T3 (es) 2022-05-19
JP2018099132A (ja) 2018-06-28
AU2021203599B2 (en) 2024-10-10
US10047398B2 (en) 2018-08-14
CN103339265B (zh) 2018-03-30
CA2813674A1 (en) 2012-04-12
MX2013003880A (es) 2013-12-02
US20220049316A1 (en) 2022-02-17
JP6946385B2 (ja) 2021-10-06
US11072831B2 (en) 2021-07-27
AU2019201493A1 (en) 2019-03-28
JP2021192636A (ja) 2021-12-23
EP3517630B1 (en) 2022-01-19
ES2721639T3 (es) 2019-08-02
AU2019201493B2 (en) 2021-03-11
EP3091085A1 (en) 2016-11-09
JP2019195340A (ja) 2019-11-14
CA2813674C (en) 2020-11-24
AU2011311452A1 (en) 2013-05-09
MX382266B (es) 2025-03-13
AU2011311452B2 (en) 2016-09-01
DK3091085T3 (da) 2019-05-06
BR112013008505A2 (pt) 2016-07-05
AU2021203599A1 (en) 2021-07-01
CN108192972A (zh) 2018-06-22
WO2012045905A3 (es) 2012-06-21
US12312642B2 (en) 2025-05-27
CN108192972B (zh) 2022-09-09
ES2562274T3 (es) 2016-03-03
EP2626431A2 (en) 2013-08-14
AU2016266009B2 (en) 2018-12-06
JP6571698B2 (ja) 2019-09-04
DK2626431T3 (en) 2015-12-21
JP2017104115A (ja) 2017-06-15
AR083357A1 (es) 2013-02-21
EP3091085B1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
KR102240323B1 (ko) 유방암 전이의 진단, 예후 및 치료 방법
KR102252332B1 (ko) 암 전이의 예후 및 치료 방법
AU2014333513B2 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
KR20150122731A (ko) 암 전이의 예후 및 치료 방법
CN105431548A (zh) 用于癌转移的诊断、预后和治疗的方法
HK40011542A (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
HK40011542B (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
HK1229858B (en) Method of designing a therapy for breast cancer metastasis
HK1229858A1 (en) Method of designing a therapy for breast cancer metastasis
HK1229858A (en) Method of designing a therapy for breast cancer metastasis

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190116

Application number text: 1020137011176

Filing date: 20130430

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190215

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190225

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20191226

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201030

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20191226

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20190225

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201030

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200623

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190823

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190215

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210109

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20201230

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201030

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200623

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190823

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190215

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210408

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210408

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240320

Start annual number: 4

End annual number: 4